Developmental Neurotoxicity Testing Protocol Design

This contract involves developing standardized in vitro protocols aimed at assessing the developmental neurotoxicity potential of foods and dietary supplements using a three-dimensional blood-brain barrier (3D BBB) model. The work includes designing exposure regimens and selecting appropriate biomarkers to ensure reliable and reproducible testing methods. The project is intended to support regulatory evaluation by offering validated approaches to detect neurotoxic effects during development. The contract is a subcontract issued by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, with the place of performance located in Silver Spring. It falls under the NAICS code 541620, which pertains to environmental consulting services, reflecting the scientific and technical nature of the work. Responses to the solicitation were due by June 12, 2026, following its posting on May 21, 2026. This initiative is part of broader efforts to enhance safety assessment protocols for consumer health products.